Logo image of VX1.DE

VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Fundamental Analysis

FRA:VX1 - Deutsche Boerse Ag - US92532F1003 - Common Stock - Currency: EUR

389.15  -3.8 (-0.97%)

Fundamental Rating

6

Overall VX1 gets a fundamental rating of 6 out of 10. We evaluated VX1 against 71 industry peers in the Biotechnology industry. VX1 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VX1 has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

VX1 had negative earnings in the past year.
In the past year VX1 has reported a negative cash flow from operations.
VX1 had positive earnings in 4 of the past 5 years.
Of the past 5 years VX1 4 years had a positive operating cash flow.
VX1.DE Yearly Net Income VS EBIT VS OCF VS FCFVX1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

VX1's Return On Assets of -4.32% is fine compared to the rest of the industry. VX1 outperforms 63.38% of its industry peers.
VX1 has a better Return On Equity (-5.99%) than 67.61% of its industry peers.
VX1's Return On Invested Capital of 15.51% is amongst the best of the industry. VX1 outperforms 91.55% of its industry peers.
VX1 had an Average Return On Invested Capital over the past 3 years of 17.35%. This is significantly above the industry average of 11.84%.
Industry RankSector Rank
ROA -4.32%
ROE -5.99%
ROIC 15.51%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
VX1.DE Yearly ROA, ROE, ROICVX1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

With an excellent Operating Margin value of 37.91%, VX1 belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
In the last couple of years the Operating Margin of VX1 has grown nicely.
VX1 has a Gross Margin of 86.03%. This is amongst the best in the industry. VX1 outperforms 83.10% of its industry peers.
In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
Industry RankSector Rank
OM 37.91%
PM (TTM) N/A
GM 86.03%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VX1.DE Yearly Profit, Operating, Gross MarginsVX1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VX1 is creating value.
Compared to 1 year ago, VX1 has less shares outstanding
Compared to 5 years ago, VX1 has less shares outstanding
VX1 has a better debt/assets ratio than last year.
VX1.DE Yearly Shares OutstandingVX1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VX1.DE Yearly Total Debt VS Total AssetsVX1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 12.70 indicates that VX1 is not in any danger for bankruptcy at the moment.
VX1's Altman-Z score of 12.70 is amongst the best of the industry. VX1 outperforms 92.96% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that VX1 is not too dependend on debt financing.
VX1's Debt to Equity ratio of 0.01 is amongst the best of the industry. VX1 outperforms 83.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 12.7
ROIC/WACC1.64
WACC9.47%
VX1.DE Yearly LT Debt VS Equity VS FCFVX1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 2.65 indicates that VX1 has no problem at all paying its short term obligations.
With a decent Current ratio value of 2.65, VX1 is doing good in the industry, outperforming 63.38% of the companies in the same industry.
VX1 has a Quick Ratio of 2.29. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
VX1 has a better Quick ratio (2.29) than 64.79% of its industry peers.
Industry RankSector Rank
Current Ratio 2.65
Quick Ratio 2.29
VX1.DE Yearly Current Assets VS Current LiabilitesVX1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

6

3. Growth

3.1 Past

VX1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.42%.
Measured over the past years, VX1 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -44.14% on average per year.
The Revenue has grown by 8.98% in the past year. This is quite good.
VX1 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.50% yearly.
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%

3.2 Future

VX1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 151.08% yearly.
Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.42% on average per year.
EPS Next Y6198.7%
EPS Next 2Y748.83%
EPS Next 3Y329.34%
EPS Next 5Y151.08%
Revenue Next Year9.5%
Revenue Next 2Y10.05%
Revenue Next 3Y9.67%
Revenue Next 5Y10.42%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
VX1.DE Yearly Revenue VS EstimatesVX1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
VX1.DE Yearly EPS VS EstimatesVX1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20 30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VX1. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 21.12, the valuation of VX1 can be described as rather expensive.
84.51% of the companies in the same industry are more expensive than VX1, based on the Price/Forward Earnings ratio.
VX1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.15.
Industry RankSector Rank
PE N/A
Fwd PE 21.12
VX1.DE Price Earnings VS Forward Price EarningsVX1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800 -1K

4.2 Price Multiples

76.06% of the companies in the same industry are more expensive than VX1, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.97
VX1.DE Per share dataVX1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VX1 may justify a higher PE ratio.
VX1's earnings are expected to grow with 329.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y748.83%
EPS Next 3Y329.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VX1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERTEX PHARMACEUTICALS INC

FRA:VX1 (5/30/2025, 7:00:00 PM)

389.15

-3.8 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners96.16%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap99.93B
Analysts77
Price Target458.75 (17.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.13%
Min EPS beat(2)-7.2%
Max EPS beat(2)-3.07%
EPS beat(4)1
Avg EPS beat(4)-133.54%
Min EPS beat(4)-527.57%
Max EPS beat(4)3.69%
EPS beat(8)4
Avg EPS beat(8)-65%
EPS beat(12)7
Avg EPS beat(12)-42.16%
EPS beat(16)10
Avg EPS beat(16)-29.51%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)2.68%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.75%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)8
Avg Revenue beat(16)0.2%
PT rev (1m)2.5%
PT rev (3m)-3.82%
EPS NQ rev (1m)-1.55%
EPS NQ rev (3m)-1.63%
EPS NY rev (1m)-1.04%
EPS NY rev (3m)-0.61%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 21.12
P/S 10.21
P/FCF N/A
P/OCF N/A
P/B 6.87
P/tB 7.57
EV/EBITDA 23.97
EPS(TTM)-0.36
EYN/A
EPS(NY)18.43
Fwd EY4.74%
FCF(TTM)-4.32
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS38.12
BVpS56.65
TBVpS51.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.32%
ROE -5.99%
ROCE 22.04%
ROIC 15.51%
ROICexc 22.97%
ROICexgc 26.06%
OM 37.91%
PM (TTM) N/A
GM 86.03%
FCFM N/A
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)17.35%
ROIC(5y)17.95%
ROICexc(3y)45.4%
ROICexc(5y)50.15%
ROICexgc(3y)65.51%
ROICexgc(5y)78.06%
ROCE(3y)24.64%
ROCE(5y)25.5%
ROICexcg growth 3Y-26.3%
ROICexcg growth 5Y-6.95%
ROICexc growth 3Y-19.26%
ROICexc growth 5Y0.61%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.03
Cap/Depr 137.41%
Cap/Sales 2.5%
Interest Coverage 181.38
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.65
Quick Ratio 2.29
Altman-Z 12.7
F-Score4
WACC9.47%
ROIC/WACC1.64
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.84%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-102.42%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%-14.71%
EPS Next Y6198.7%
EPS Next 2Y748.83%
EPS Next 3Y329.34%
EPS Next 5Y151.08%
Revenue 1Y (TTM)8.98%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%2.96%
Revenue Next Year9.5%
Revenue Next 2Y10.05%
Revenue Next 3Y9.67%
Revenue Next 5Y10.42%
EBIT growth 1Y-1.84%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year827.23%
EBIT Next 3Y131%
EBIT Next 5Y70.46%
FCF growth 1Y-132.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.06%
OCF growth 3YN/A
OCF growth 5YN/A